The priority that will unite all life sciences companies in 2016 is the pursuit of greater agility. As long as organisations keep taking a short-term view, investing in standalone information management systems for each new business requirement, the only thing they’ll successfully grow is cost, warns Mark Evenepoel, Group CEO at Amplexor Life Sciences. The real focus should be flexibility and responsiveness to whatever the market demands next.
Current Edition
Current Edition
Subsection - CDMO
Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.
Continue readingSubsection - Injectables
Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.
Continue readingSubsection - Neurodegenerative Diseases
Exploring emerging approaches to neurodegenerative disease research and treatment.
Continue readingSubsection - Nasal & Pulmonary
Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.
Continue reading
